Cargando…
Development of surface-engineered PLGA nanoparticulate-delivery system of Tet1-conjugated nattokinase enzyme for inhibition of Aβ(40) plaques in Alzheimer’s disease
According to the World Health Organization, globally there are around 18 million patients suffering from Alzheimer’s disease (AD), and this number is expected to double by 2025. The pathophysiology of AD includes selective deposition of Aβ peptide in the mitochondria of cells, which inhibits uptake...
Autores principales: | Bhatt, Prakash Chandra, Verma, Amita, Al-Abbasi, Fahad A, Anwar, Firoz, Kumar, Vikas, Panda, Bibhu Prasad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732557/ https://www.ncbi.nlm.nih.gov/pubmed/29263666 http://dx.doi.org/10.2147/IJN.S144545 |
Ejemplares similares
-
Fabrication, optimization, and characterization of umbelliferone β-D-galactopyranoside-loaded PLGA nanoparticles in treatment of hepatocellular carcinoma: in vitro and in vivo studies
por: Kumar, Vikas, et al.
Publicado: (2017) -
Commentary: L-3-n-butylphthalide Rescues Hippocampal Synaptic Failure and Attenuates Neuropathology in Aged APP/PS1 Mouse Model of Alzheimer's Disease
por: Bhatt, Prakash C., et al.
Publicado: (2017) -
Concepts and practices used to develop functional PLGA-based nanoparticulate systems
por: Sah, Hongkee, et al.
Publicado: (2013) -
Anticancer nanoparticulate polymer‐drug conjugate
por: Feng, Quanyou, et al.
Publicado: (2016) -
Curcumin Loaded-PLGA Nanoparticles Conjugated with Tet-1 Peptide for Potential Use in Alzheimer's Disease
por: Mathew, Anila, et al.
Publicado: (2012)